Literature DB >> 24960627

Design and synthesis of novel soluble 2,5-diketopiperazine derivatives as potential anticancer agents.

Shengrong Liao1, Xiaochu Qin2, Ding Li3, Zhengchao Tu2, Jinsheng Li1, Xuefeng Zhou1, Junfeng Wang1, Bin Yang1, Xiuping Lin1, Juan Liu1, Xianwen Yang1, Yonghong Liu4.   

Abstract

Non-protected 2,5-diketopiperazine derivatives have poor solubility thus with negative impact on their bioavailability. In the present study, twenty-one novel soluble mono-protected, and three non-protected 2,5-diketopiperazine derivatives were designed and synthesized. Their anticancer activity to ten cell lines were evaluated by using CCK8 assay, and the results showed that about half of the mono-protected derivatives had broad-spectrum anticancer activity. Among allyl-protected derivatives, compound 4m had strong activity to all the cell lines (IC50 = 0.5-4.5 μM), especially to the cancer cell lines U937 (IC50 = 0.5 μM) and K562 (IC50 = 0.9 μM). Compound 4m could become a lead compound for further development for anticancer agents.
Copyright © 2014 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  2,5-Diketopiperazine derivative; Anticancer agent; Protective group; Solubility

Mesh:

Substances:

Year:  2014        PMID: 24960627     DOI: 10.1016/j.ejmech.2014.06.030

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  2 in total

1.  2,5-Diketopiperazine Derivatives as Potential Anti-Influenza (H5N2) Agents: Synthesis, Biological Evaluation, and Molecular Docking Study.

Authors:  Chanakan Winyakul; Weerachai Phutdhawong; Poomipat Tamdee; Jitnapa Sirirak; Thongchai Taechowisan; Waya S Phutdhawong
Journal:  Molecules       Date:  2022-06-29       Impact factor: 4.927

2.  Facile synthesis and biological evaluation of tryptamine-piperazine-2,5-dione conjugates as anticancer agents.

Authors:  Jiang-Ping Meng; Shi-Qiang Li; Yan Tang; Zhi-Gang Xu; Zhong-Zhu Chen; Li-Xia Gao
Journal:  RSC Adv       Date:  2021-08-17       Impact factor: 4.036

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.